文献速递流行病学与生物统计临床试验与 GCP

临床试验结果依法报告合规性:队列研究

Compliance with legal requirement to report clinical trial results on ClinicalTrials.gov: a cohort study.
PubMed 文献 · Lancet · 2020-01-17

该队列研究评估了FDAAA 2007最终规则要求的临床试验结果在ClinicalTrials.gov上的报告合规性。合规性自2018年7月以来未见改善,中位延迟为424天。

要点

  • 中位报告延迟424天,比法定1年要求多59天。

核心结论

  • FDAAA 2007最终规则的合规性差且未改善,需有效执法和申办者行动。

研究设计与样本

  • 队列研究,纳入所有FDAAA适用且应报告结果的试验,排除不适用、未到期和获延迟报告许可的试验。
  • 从2018年3月至2019年9月每月下载ClinicalTrials.gov数据,横断面分析基于2019年9月16日数据。

主要发现

  • 从主要完成日期到提交日期的中位延迟为424天(95% CI 412-435),比法定1年要求多59天。

关键数值与推荐

  • 合规定义为在主要完成日期后1年内提交结果。
  • 报告定义为结果已提交并公开可用或正在质量审查中。

临床怎么用

  • 申办者应确保在试验完成后1年内提交结果至ClinicalTrials.gov。
  • 公开审计各申办者合规性可能有助于改善报告率。

局限性

  • 仅基于ClinicalTrials.gov数据,可能未涵盖所有报告渠道。
  • 合规性评估限于FDAAA适用试验,外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Failure to report the results of a clinical trial can distort the evidence base for clinical practice, breaches researchers' ethical obligations to participants, and represents an important source of research waste. The Food and Drug Administration Amendments Act (FDAAA) of 2007 now requires sponsors of applicable trials to report their results directly onto ClinicalTrials.gov within 1 year of completion. The first trials covered by the Final Rule of this act became due to report results in January, 2018. In this cohort study, we set out to assess compliance. METHODS: We downloaded data for all registered trials on ClinicalTrials.gov each month from March, 2018, to September, 2019. All cross-sectional analyses in this manuscript were performed on data extracted from ClinicalTrials.gov on Sept 16, 2019; monthly trends analysis used archived data closest to the 15th day of each month from March, 2018, to September, 2019. Our study cohort included all applicable trials due to report results under FDAAA. We excluded all non-applicable trials, those not yet due to report, and those given a certificate allowing for delayed reporting. A trial was considered reported if results had been submitted and were either publicly available, or undergoing quality control review at ClinicalTrials.gov. A trial was considered compliant if these results were submitted within 1 year of the primary completion date, as required by the legislation. We described compliance with the FDAAA 2007 Final Rule, assessed trial characteristics associated with results reporting using logistic regression models, described sponsor-level reporting, examined trends in reporting, and described time-to-report using the Kaplan-Meier method. FINDINGS: 4209 trials were due to report results; 1722 (40·9%; 95% CI 39·4-42·2) did so within the 1-year deadline. 2686 (63·8%; 62·4-65·3) trials had results submitted at any time. Compliance has not improved since July, 2018. Industry sponsors were significantly more likely to be compliant than non-industry, non-US Government sponsors (odds ratio [OR] 3·08 [95% CI 2·52-3·77]), and sponsors running large numbers of trials were significantly more likely to be compliant than smaller sponsors (OR 11·84 [9·36-14·99]). The median delay from primary completion date to submission date was 424 days (95% CI 412-435), 59 days higher than the legal reporting requirement of 1 year. INTERPRETATION: Compliance with the FDAAA 2007 is poor, and not improving. To our knowledge, this is the first study to fully assess compliance with the Final Rule of the FDAAA 2007. Poor compliance is likely to reflect lack of enforcement by regulators. Effective enforcement and action from sponsors is needed; until then, open public audit of compliance for each individual sponsor may help. We will maintain updated compliance data for each individual sponsor and trial at fdaaa.trialstracker.net. FUNDING: Laura and John Arnold Foundation.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. DeVito NJ, Bacon S, Goldacre B, et al. Compliance with legal requirement to report clinical trial results on ClinicalTrials.gov: a cohort study. Lancet. 2020. PMID: 31958402. doi:10.1016/S0140-6736(19)33220-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。